Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Cash flows from operating activities
Net loss	$ (43,159)	$ (31,350)
Adjustments to reconcile net loss to net cash, cash equivalents, and restricted cash used in operating activities
Depreciation and amortization	3,178	2,903
Amortization of convertible notes debt discount		4,389
Gain on debt extinguishments, net	(2,298)
Stock‑based compensation expense	4,944	3,709
Change in fair value of warrant liability		1,252
Change in contingent consideration	1,622	818
Provision for doubtful accounts	193	296
Accrued interest, amortization of debt issuance costs and other	2,706	1,418
Changes in operating assets and liabilities:
Accounts receivable	11,454	(10,308)
Other current assets	1,369	(6,588)
Other long-term assets and liabilities	875	(1,808)
Accounts payable and other accrued liabilities	(7,425)	11,654
Deferred revenue	(1,682)	2,249
Net cash and cash equivalents and restricted cash used in operating activities	(28,223)	(21,366)
Cash flows from investing activities
Purchase of property and equipment	(2,241)	(1,945)
Patent costs and intangible asset acquisition, net	(306)	(232)
Payments to acquire Oncimmune assets		(750)
Net cash and cash equivalents and restricted cash used in investing activities	(2,547)	(2,927)
Cash flows from financing activities
Proceeds from initial public offering		72,000
Proceeds from the issuance of common stock	16,343
Proceeds from issuance of common stock under employee stock purchase plan	328
Proceeds from exercise of stock options	769	1,340
Proceeds from issuances of convertible notes payable		12,955
Proceeds from term loan and notes payable	30,078	3,085
Repayment of term loan and notes payable	(45,428)
Payment of debt issuance costs	(164)
Equity financing costs	(664)	(8,243)
Other		(6)
Net cash and cash equivalents and restricted cash provided by financing activities	1,262	81,131
Net increase (decrease) in cash and cash equivalents and restricted cash	(29,508)	56,838
Cash, cash equivalents, and restricted cash ‑ beginning of period	62,306	5,468
Cash, cash equivalents, and restricted cash ‑ end of period	32,798	62,306
Supplemental cash flow information
Conversion of preferred stock into common stock		193,959
Conversion of convertible notes and accrued interest into common stock		26,616
Reclassification of put option liability to additional paid-in capital		6,650
Value of put option recorded at issuance of convertible debt payable		3,389
Cash paid for interest	1,676	1,844
Reclassification of warrant liability to additional paid-in capital		$ 1,624
Non-cash debt issuance costs included in Accrued liabilities	$ 15